CELLECTISAct. Nom. Aktie [WKN DE: A0MKPR / ISIN: FR0010425595]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu CELLECTISAct. Nom.

20.07.17		Cellectis S.A.: Calyxt Announces Pricing of $56.0 Million Initial Public Offering (Businesswire)
10.07.17		Cellectis: Calyxt Announces Proposed Initial Public Offering of $100.0 Million (Businesswire)
27.06.17		First in Human Administration of UCART123 in Cellectis’ AML Phase I Clinical Trial at Weill Cornell Medicine, NewYork-Presbyterian Hospital (Businesswire)
23.06.17		Calyxt Files Registration Statement for Proposed Initial Public Offering (Businesswire)
23.01.17		Cellectis Studies Safety in New CAR Architecture Controlling CAR T-Cell Functions (Businesswire)
22.11.16		Cellectis Reports Financial Results for 3rd Quarter and First Nine Months 2016 (Businesswire)
21.11.16		Cellectis to Participate in Oppenheimer Life Sciences Summit, NY & in Piper Jaffray 28th Annual Health Care Conference, NY (Businesswire)
15.11.16		Cellectis Announces Successful cGMP Manufacturing for Second Product Candidate: UCART123 (Businesswire)
07.11.16		Cellectis Announces Two Oral Presentations and One Poster at the 2016 ASH Annual Meeting (Businesswire)
31.10.16		Cellectis Hosts World’s First Gene Edited Dinner in NYC (Businesswire)
04.10.16		Cellectis Announces the Issuance of U.S. Patent 9,458,439 Following U.S. Patent 8,921,332 Issued in December 2014 (Businesswire)
27.09.16		Cellectis Wins 2016 Most Innovative European Biotech SME Award for Healthcare (Businesswire)
08.09.16		Cellectis Reports 2nd Quarter and First Half Year 2016 Financial Results (Businesswire)
27.06.16		MIT Technology Review Names Cellectis on Annual List of 50 Smartest Companies for Second Consecutive Year (Businesswire)
27.06.16		Cellectis Named 2016 Technology Pioneer by the World Economic Forum (Businesswire)
20.06.16		Cellectis Announces First Patient Treated in Phase 1 Trial of UCART19 in Pediatric Acute B Lymphoblastic Leukemia (B-ALL) (Businesswire)
19.05.16		Cellectis S.A. Reports Results from Shareholders’ General Meeting Held on May 17, 2016 (Businesswire)
11.05.16		Cellectis Reports First Quarter 2016 Financial Results (Businesswire)
02.05.16		Cellectis to Present Data on Its Allogeneic CAR T-Cell Programs at the 19th American Society of Gene & Cell Therapy Annual Meeting (Businesswire)
21.03.16		Cellectis Announces RetroNectin® Supply and License Agreement with Takara Bio Inc. (Businesswire)
16.03.16		Cellectis and MabQuest Announce Immunotherapy Partnership on New Class of PD-1 Antagonist Monoclonal Antibodies (Businesswire)
08.03.16		Cellectis Announces Presentation at the Cowen and Company 36th Annual Health Care Conference in Boston, March 7-9, 2016 (Businesswire)
02.03.16		Cellectis Subsidiary Calyxt, Acquires Land for New Headquarters Facility (Businesswire)
19.01.16		Cellectis Enters into New Agreement with CELLforCURE for the cGMP Manufacturing of UCART123 for Hematological Malignancies (Businesswire)
11.01.16		Cellectis Announces a New CAR Architecture Controlling CAR T-Cell Functions (Businesswire)
07.01.16		Cellectis Announces Chief Medical Officer Appointment to Senior Leadership Team (Businesswire)
23.12.15		Cellectis Files First Clinical Trial Application for UCART19, an Allogeneic Gene Edited CAR T-Cell Product for Hematological Malignancies (Businesswire)
21.12.15		Cellectis Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, January 11 - 14, 2016 (Businesswire)
03.12.15		Cellectis Announces Conference Call to Discuss UCART19 Development Collaboration with Pfizer and Servier (Businesswire)
30.11.15		Cellectis Announces Presentations at Upcoming Conferences (Businesswire)
19.11.15		Servier Exercises Exclusive Worldwide Licensing Option with Cellectis for UCART19, an Allogeneic CAR-T Cell Therapy for Hematological Malignancies (Businesswire)
16.11.15		Cellectis Reports Third Quarter and First Nine Months 2015 Financial Results (Businesswire)
05.11.15		Cellectis to Present Data on its Allogeneic CAR T-Cell Immunotherapy Product Candidates during the Upcoming ASH Annual Meeting (Businesswire)
05.11.15		Cellectis: UCART19: First in Man Proof of Concept to Be Presented at 2015 ASH Annual Meeting (Businesswire)
28.10.15		Successful GMP Production Process for UCART19 (Businesswire)
09.09.15		Cellectis Announces Presentations at Upcoming Conferences (Businesswire)
08.09.15		Cellectis Reports Second Quarter and First Half Year 2015 Financial Results (Businesswire)
03.09.15		MD Anderson Cancer Center and Cellectis Announce a Broad Preclinical and Clinical Strategic Alliance in Cancer Immunotherapy (Businesswire)
26.08.15		Cellectis to Present Data on its CAR T-Cell Immunotherapy Programs During Upcoming Conferences (Businesswire)
16.07.15		Cellectis Announces Publication of an Article in Cancer Research on Allogeneic CAR T-cell Immunotherapies (Businesswire)
08.07.15		Cellectis Reaches Milestone in Servier Collaboration (Businesswire)
10.06.15		Cellectis Announces Promising Study on Next Generation Engineered Allogeneic CAR T-cells (Businesswire)
09.06.15		S&W Seed Company and Calyxt, Inc. Announce Alfalfa Seed Collaboration (Businesswire)
09.06.15		Cellectis Reports First Quarter 2015 Financial Results (Businesswire)
05.06.15		Cellectis to Present Data on its Allogeneic CAR T-Cell Immunotherapy Programs at the European Hematology Association Annual Meeting (Businesswire)
02.06.15		Weill Cornell Medical College and Cellectis Announce Research Alliance Advancing Drug Discovery and the Translation of Novel Immunotherapies in Leukemia (Businesswire)
20.05.15		Cellectis SA Combined General Shareholders’ Meeting of May 18, 2015 (Businesswire)
08.05.15		Cellectis S.A. to Present Data on its Allogeneic CAR T Cell Programs at American Society of Gene & Cell Therapy Annual Meeting (Businesswire)
05.05.15		Cellectis S.A. Announces Calyxt is New Name for Its Plant Sciences Subsidiary (Businesswire)
16.04.15		Cellectis Plant Sciences, Inc. Locks Early CRISPR Intellectual Property Uses in Plants (Businesswire)

Zurück | 1 | 2 | 3 | 4 | Weiter

Newssuche

Meistgelesene Nachrichten

Pierer Mobility-Aktie schwach: Gehälter für Angestellte von insolventer KTM noch vor Weihnachten

Bundesheer wirbt nach KTM-Insolvenz um Mitarbeiter - Pierer Mobility-Aktie im Plus

Ethereum Kurs Prognose: ETH massiv unterbewertet! Fällt jetzt das ATH?

Zalando-Aktie im Plus, ABOUT YOU-Aktie mit Kurssprung: Zalando unterbreitet Übernahmeangebot für ABOUT YOU

NASDAQ 100: Palantir und MicroStrategy vor der Aufnahme - Was Anleger wissen sollten

TUI-Aktie im Plus: Gewinne dank Urlauber-Ansturm

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	13.12.2024 16:12
Kaufwert:	EUR
	Hinzufügen Speichern